Titan Pharmaceuticals Inc (TTNP) - Total Liabilities
Based on the latest financial reports, Titan Pharmaceuticals Inc (TTNP) has total liabilities worth $263.00K USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Titan Pharmaceuticals Inc (TTNP) equity growth momentum to track the company's year-over-year net asset growth rate.
Titan Pharmaceuticals Inc - Total Liabilities Trend (1995–2024)
This chart illustrates how Titan Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Titan Pharmaceuticals Inc generate to measure how efficiently the company converts operating cash flow to free cash.
Titan Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Titan Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Djasa Ubersakti Tbk
JK:PTDU
|
Indonesia | Rp158.79 Billion |
|
Ladangbaja Murni PT Tbk
JK:LABA
|
Indonesia | Rp31.52 Billion |
|
PT Winner Nusantara Jaya Tbk
JK:WINR
|
Indonesia | Rp107.74 Billion |
|
Eo2 Société Anonyme
PA:ALEO2
|
France | €18.63 Million |
|
Tedea Technological Development and Automation Ltd
TA:TEDE
|
Israel | ILA4.79 Million |
|
Digitalist Group Oyj
HE:DIGIGR
|
Finland | €49.61 Million |
|
Scandinavian Brake Systems A/S
CO:SBS
|
Denmark | Dkr32.30 Million |
|
The North American Income Trust plc
LSE:NAIT
|
UK | GBX41.74 Million |
Liability Composition Analysis (1995–2024)
This chart breaks down Titan Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TTNP market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Titan Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Titan Pharmaceuticals Inc (1995–2024)
The table below shows the annual total liabilities of Titan Pharmaceuticals Inc from 1995 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $483.00K | -66.55% |
| 2023-12-31 | $1.44 Million | -46.42% |
| 2022-12-31 | $2.69 Million | -5.64% |
| 2021-12-31 | $2.86 Million | -37.30% |
| 2020-12-31 | $4.55 Million | -43.69% |
| 2019-12-31 | $8.09 Million | +11.36% |
| 2018-12-31 | $7.26 Million | -9.74% |
| 2017-12-31 | $8.05 Million | +46.97% |
| 2016-12-31 | $5.48 Million | -13.04% |
| 2015-12-31 | $6.30 Million | -48.55% |
| 2014-12-31 | $12.24 Million | -3.34% |
| 2013-12-31 | $12.66 Million | -73.59% |
| 2012-12-31 | $47.95 Million | +58.29% |
| 2011-12-31 | $30.30 Million | +180.39% |
| 2010-12-31 | $10.80 Million | +174.73% |
| 2009-12-31 | $3.93 Million | +0.85% |
| 2008-12-31 | $3.90 Million | -8.36% |
| 2007-12-31 | $4.26 Million | +25.40% |
| 2006-12-31 | $3.39 Million | +8.23% |
| 2005-12-31 | $3.14 Million | -14.60% |
| 2004-12-31 | $3.67 Million | +9.91% |
| 2003-12-31 | $3.34 Million | -15.31% |
| 2002-12-31 | $3.94 Million | -31.56% |
| 2001-12-31 | $5.76 Million | +134.02% |
| 2000-12-31 | $2.46 Million | +29.63% |
| 1999-12-31 | $1.90 Million | +18.75% |
| 1998-12-31 | $1.60 Million | -77.78% |
| 1997-12-31 | $7.20 Million | +89.47% |
| 1996-12-31 | $3.80 Million | -59.14% |
| 1995-12-31 | $9.30 Million | -- |
About Titan Pharmaceuticals Inc
As of October 1, 2025, Titan Pharmaceuticals, Inc. was acquired by KE Sdn Bhd, in a reverse merger transaction. Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York.